Drug Profile
TLY 012
Alternative Names: TLY012Latest Information Update: 16 Dec 2021
Price :
$50
*
At a glance
- Originator Theraly Fibrosis
- Developer Johns Hopkins University School of Medicine; Theraly Fibrosis
- Class Antifibrotics; Hepatoprotectants; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Immunosuppressants; TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Fibrosis; Liver cirrhosis; Pancreatitis; Systemic scleroderma
Most Recent Events
- 16 Dec 2021 Phase-I clinical trials in Fibrosis in USA (Parenteral) (D&D Pharmatech pipeline, December 2021)
- 16 Dec 2021 Phase-I clinical trials in Liver cirrhosis in USA (Parenteral) (D&D Pharmatech pipeline, December 2021)
- 16 Dec 2021 Phase-I clinical trials in Pancreatitis in USA (Parenteral) (D&D Pharmatech pipeline, December 2021)